Study to Assess the Non-inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer (PAMOJECT)

Exclusion Criteria

• •Has a history of hypersensitivity to the Investigational Medicinal Product or drugs with a similar chemical structure
• •Has previously received a GnRH analogue, estrogens or a steroidal anti -androgen within the last year preceding the study
• •Concomitant anti-coagulation treatment
• •Patient who underwent an orchidectomy or who is scheduled to receive an orchidectomy during the course of this study
• •Patient with known spinal medullar compression